Switch to Tirzepatide in T2D More Effective Than Upping Dulaglutide Dose

You May Be Interested In:Boeing jet returns to US from China amid tariff war



(MedPage Today) — Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide (Mounjaro) rather than increasing the dose of the earlier-generation GLP-1 receptor agonist, an open…

share Paylaş facebook pinterest whatsapp x print

Similar Content

Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still Ahead
Embattled TAVR Device Myval Meets Expectations in Trial, but Trouble Still Ahead
Noninvasive Stents as Good as Surgery for Triple-Vessel Disease
Noninvasive Stents as Good as Surgery for Triple-Vessel Disease
‘Alarming Disparities’ in Cancer Trends and Shift to Women, Younger Adults
‘Alarming Disparities’ in Cancer Trends and Shift to Women, Younger Adults
Tirzepatide Slashes Progression From Prediabetes to T2D
Tirzepatide Slashes Progression From Prediabetes to T2D
Topical Ivermectin Among Rx Options for Ocular Rosacea
Topical Ivermectin Among Rx Options for Ocular Rosacea
FDA Clears NSAID/Triptan Combo for Migraine in Adults
FDA Clears NSAID/Triptan Combo for Migraine in Adults
The News Link | © 2025 | News